Roivant Sciences (ROIV) Current Deferred Revenue (2021 - 2025)

Roivant Sciences' Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $1.2 million for Q1 2025.

• Quarterly Current Deferred Revenue fell 71.98% year-over-year to $1.2 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $1.2 million (down 71.98% YoY) and the FY2025 annual result came in at $1.2 million, down 71.98% from the prior year.
• Current Deferred Revenue was $1.2 million for Q1 2025 at Roivant Sciences, down from $3.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $12.4 million in Q1 2023 and bottomed at $1.2 million in Q1 2025.
• A 5-year average of $6.4 million and a median of $5.9 million in 2021 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue surged 71.46% — and 2024, when it tumbled 74.83%.
• Roivant Sciences' Current Deferred Revenue stood at $5.9 million in 2021, then soared by 31.73% to $7.8 million in 2022, then sank by 39.78% to $4.7 million in 2023, then tumbled by 35.31% to $3.0 million in 2024, then slumped by 61.54% to $1.2 million in 2025.
• Business Quant data shows ROIV's Current Deferred Revenue at $1.2 million in Q1 2025, $3.0 million in Q4 2024, and $3.4 million in Q3 2024.